A new report “Counting the Cost of Respiratory Disease”, by Health Enterprise East, has named Aseptika as one of four Medtech companies to watch.
The NHS Long Term Plan identified respiratory disease as a top clinical priority, with a need for innovation in paediatric asthma treatment.
The report highlighted that hospital admissions due to respiratory diseases have increased sharply over the last seven years at three times the rate of all other admissions. 12.7 million people in the UK are now living with respiratory disease, costing the NHS £11 billion per year. The economic cost to the NHS for asthma is approximated at £3 billion each year.
The report by the MedTech Navigator, written and delivered by Health Enterprise East and part-funded by the European Development Fund (ERDF), names Aseptika as one of four companies to watch. Aseptika’s Asthma+me self-care solution for children aged 6-12 years treated in outpatient clinics with moderate-to-severe or difficult asthma, was one of the innovations highlighted in the report.
Asthma+me supports families to self-care with wireless medical monitors, Activ8rlives PUFFClickerTM smart tracker for pressurised metered-dose inhalers (pMDIs), medication diaries, trigger alerts for pollution/pollen/weather, symptoms tracking, interactive and printable Care and Action Plans, an extensive integrated educational syllabus and weekly reports going directly into their hospital records. This evidence-based integrated solution has been co-designed with a leading NHS paediatrician, to significantly reduce utilisation of NHS services by families of these children.
The other SME companies included in the report were: Cambridge Respiratory Innovations Ltd, My mHealth and Owlstone Medical.
Asthma is particularly prevalent in children, with around 20% of all patients (1.1 million) under the age of 15-year in the UK of which 110,000 have moderate-to-severe or difficult asthma with an estimated cost to the NHS of £500 million each year.